Primary Surgery or Interval Debulking for Advanced Epithelial Ovarian Cancer: Does It Matter?

被引:26
作者
Markauskas, Algirdas [1 ]
Mogensen, Ole [1 ]
Christensen, Rene dePont [2 ]
Jensen, Pernille Tine [1 ]
机构
[1] Odense Univ Hosp, Dept Obstet & Gynaecol, DK-5000 Odense C, Denmark
[2] Univ Southern Denmark, Res Unit Gen Practice, Odense, Denmark
关键词
Debulking surgery; Epithelial ovarian cancer; Surgical complexity; Postoperative morbidity; Survival; NEOADJUVANT CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; QUALITY; RISK;
D O I
10.1097/IGC.0000000000000241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of the present study was to investigate the surgical complexity, the postoperative morbidity, and the survival of the women after primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) for advanced epithelial ovarian cancer. Materials and Methods: We consecutively included all patients who underwent debulking surgery at our institution between January 2007 and December 2012 for stages IIIc and IV of epithelial ovarian cancer. Results: Of the 332 patients included, 165 (49.7%) underwent PDS, and 167 (50.3%) had NACT-IDS. Complete intraperitoneal cytoreduction was achieved in 70.9% after PDS and in 59.9 % after NACT-IDS. Residual disease of greater than 1 cm was left in 18.5% and 27.5% after PDS and NACT-IDS, respectively. Compared with NACT-IDS, PDS was associated with higher surgical complexity (P < 0.001), longer operating time (P < 0.001), greater blood loss (P < 0.001), longer hospitalization (P = 0.001), and a higher rate of major postoperative complications (26.7% vs 16.8%). No statistical difference in the median overall survival (OS) was found between the patients having complete cytoreduction and residual disease of 1 cm or less after NACT-IDS. Furthermore, no statistical difference in the median OS was found between the patients with macroscopic residual disease (<= 1 vs >1 cm) after NACT-IDS. Patients with residual disease of greater than 1 cm after PDS had a median OS of 15 months. Conclusions: We suggest that NACT-IDS may be a better treatment alternative for the group of highly selected women not suitable for PDS, where expected suboptimal cytoreduction does not have any appreciable survival benefit and exposes them for unnecessary risks. A substantial number of women who receive either PDS or NACT-IDS have greater than 1 cm of tumor tissue left after the operation. These women probably have no survival benefit from the operation, and future studies should focus on how to select these women preoperatively.
引用
收藏
页码:1420 / 1428
页数:9
相关论文
共 23 条
  • [11] DEVITA VT, 1983, CANCER, V51, P1209, DOI 10.1002/1097-0142(19830401)51:7<1209::AID-CNCR2820510707>3.0.CO
  • [12] 2-J
  • [13] Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study
    Fago-Olsen, Carsten Lindberg
    Ottesen, Bent
    Kehlet, Henrik
    Antonsen, Sofie L.
    Christensen, Ib J.
    Markauskas, Algirdas
    Mosgaard, Berit J.
    Ottosen, Christian
    Soegaard, Charlotte H.
    Soegaard-Andersen, Erik
    Hoegdall, Claus
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 132 (02) : 292 - 298
  • [14] Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma
    Fagotti, Anna
    Ferrandina, Gabriella
    Fanfani, Francesco
    Garganese, Giorgia
    Vizzielli, Giuseppe
    Carone, Vito
    Salerno, Maria Giovanna
    Scambia, Giovanni
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2008, 199 (06) : 642.e1 - 642.e6
  • [15] GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727
  • [16] Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?
    Hynninen, Johanna
    Lavonius, Maija
    Oksa, Sinikka
    Grenman, Seija
    Carpen, Olli
    Auranen, Annika
    [J]. GYNECOLOGIC ONCOLOGY, 2013, 128 (02) : 229 - 232
  • [17] Kehoe SM, 2013, 2013 AM SOC CLIN ONC
  • [18] Mackay HJ, 2011, CURR ONCOL, V18, P84
  • [19] Quality of complication reporting in the surgical literature
    Martin, RCG
    Brennan, MF
    Jaques, DP
    [J]. ANNALS OF SURGERY, 2002, 235 (06) : 803 - 812
  • [20] Multi-Center Evaluation of Post-Operative Morbidity and Mortality after Optimal Cytoreductive Surgery for Advanced Ovarian Cancer
    Rafii, Arash
    Stoeckle, Eberhard
    Jean-Laurent, Mehdi
    Ferron, Gwenael
    Morice, Philippe
    Houvenaeghel, Gilles
    Lecuru, Fabrice
    Leblanc, Eric
    Querleu, Denis
    [J]. PLOS ONE, 2012, 7 (07):